PharVision Advisers’s Amphenol APH Stock Holding History

PharVision Advisers’s Portfolio APH Stock Details APH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,839	Closed	-$249K	–	127
2025 Q4	$249K	Sell	1,839 -684	-27%	-$91.5K	0.13%	391
2025 Q3	$312K	Buy	+2,523	New	+$277K	0.18%	207

Other funds holding APH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PharVision Advisers's APH Position: Q1 2026 in Review

PharVision Advisers sold out of Amphenol (APH) in Q1 2026, closing a stake of 1,839 shares — an estimated $249K sold.

PharVision Advisers first reported a position in APH in Q3 2025 and held it in 2 quarters. The position peaked at $312K in Q3 2025. 2,115 funds tracked by Wall St. Rank hold APH as of Q1 2026.

PharVision Advisers reported no remaining Amphenol position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,839 Amphenol shares in Q1 2026, an estimated $249K.
PharVision Advisers first reported a position in Amphenol in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Amphenol position peaked at $312K in Q3 2025.
2,115 funds tracked by Wall St. Rank held Amphenol as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.